TABLE 2.
HLA class I supertypes and HIV-1 control in African Americans from the REACH (1996-2001) and HERS (1993-2000) cohorts
| HLA class I supertype | No. (%) of patientsa |
P valueb | POR (95% CI)c | ||
|---|---|---|---|---|---|
| Controllers (n = 76) | Intermediates (n = 169) | Noncontrollers (n = 93) | |||
| A1s | 16 (21.1) | 30 (17.8) | 16 (17.2) | 0.5 | 0.9 (0.5-1.4) |
| No A*32 | 10 (14.3) | 25 (15.2) | 16 (17.2) | 0.6 | 1.1 (0.7-2.1) |
| A2s | 31 (40.8) | 78 (46.2) | 36 (38.7) | 0.7 | 0.9 (0.6-1.4) |
| A24s | 36 (47.4) | 78 (46.2) | 48 (51.6) | 0.6 | 1.1 (0.8-1.7) |
| A3s | 52 (68.4) | 106 (62.7) | 56 (60.2) | 0.3 | 0.8 (0.5-1.2) |
| No A*74 | 36 (60.0) | 81 (56.3) | 51 (58.0) | 0.9 | 0.9 (0.6-1.5) |
| B7s | 40 (52.6) | 115 (68.1) | 75 (80.7) | <0.001 | 2.4 (1.5-3.7) |
| No B*35 | 31 (46.3) | 91 (62.8) | 56 (75.7) | <0.001 | 2.3 (1.5-3.7) |
| No B*35 or B*53 | 25 (41.0) | 48 (47.1) | 32 (64.0) | 0.02 | 1.8 (1.1-3.1) |
| No B*35, B*53, or B22d | 25 (41.0) | 46 (46.0) | 31 (63.3) | 0.02 | 1.8 (1.1-3.0) |
| No B*35, B*53, B22,d or B*81 | 20 (35.7) | 42 (43.8) | 31 (63.3) | <0.01 | 2.1 (1.3-3.6) |
| B27s | 25 (32.9) | 53 (31.4) | 23 (24.7) | 0.2 | 0.8 (0.5-1.2) |
| No B*1510 | 24 (32.0) | 40 (25.6) | 14 (16.7) | 0.03 | 0.6 (0.4-0.9) |
| No B*1510 or B*14 | 13 (20.3) | 28 (19.4) | 12 (14.6) | 0.36 | 0.8 (0.4-1.4) |
| B44s | 17 (22.4) | 70 (41.4) | 38 (40.9) | 0.02 | 1.6 (1.1-2.5) |
| No B*44 | 10 (14.5) | 44 (30.8) | 24 (30.4) | 0.04 | 1.7 (1.0-2.7) |
| No B*44 or B*45 | 4 (6.4) | 30 (23.3) | 14 (20.3) | 0.05 | 1.8 (1.0-3.2) |
| B58s | 42 (55.3) | 42 (24.9) | 19 (20.4) | <0.0001 | 0.3 (0.2-0.5) |
| No B*57 | 17 (33.3) | 31 (19.6) | 17 (18.7) | 0.07 | 0.6 (0.4-1.1) |
| No B*57 or B*5801 | 9 (20.9) | 20 (13.6) | 8 (9.7) | 0.09 | 0.6 (0.3-1.1) |
| B62s | 7 (9.2) | 6 (3.6) | 1 (1.1) | 0.01 | 0.3 (0.1-0.7) |
a
Disease control categories were based on the average favorable (controllers; VL of <1,000 copies/ml and CD4 count of >450 cells/ml), unfavorable (noncontrollers; VL of >16,000 copies/ml and CD4 count of <450 cells/ml), and remaining (intermediates) VL and CD4 count combinations.
b
Assessed by rank score Cochran-Mantel-Haenszel test for trend.
c
POR, proportional odds ratio.
d
B22 serogroup includes B*54 to B*56.